Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: A direct comparison with systemic IL-12 protein therapy

Journal of Immunotherapy

Volumn 22, Issue 2, 1999, Pages 135-144

  Rakhmilevich, Alexander L ^a,b   Timmins, James G ^a,c   Janssen, Karen ^a,d   Pohlmann, Edward L ^a,e   Sheehy, Michael J ^a,b   Yang, Ning Sun ^a,b  

^a Auragen Inc   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Breakthrough Development Co   (United States)

^d Agracetus   (United States)

^e Ophidian Pharmaceuticals Inc   (United States)

Author keywords

Cancer gene therapy; Gene gun; Interleukin 12; Mice; Particle bombardment; Toxicity; Transfection

Indexed keywords

INTERLEUKIN 12;

ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; GENE GUN; GENE THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, LY; BIOLISTICS; FEMALE; GENE THERAPY; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; NEOPLASMS, EXPERIMENTAL; SPLENOMEGALY; WEIGHT LOSS;

EID: 0033017095     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199903000-00005     Document Type: Article

References (30)

1. Brunda MJ, Luistro L. Warrier R. et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
2. Nastala CL. Edington HD. McKinney TG. et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994;153:1697-706.
3. Zou J-P, Yamamoto N. Fujii T, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells, hit Immunol 1995:7:1135-45.
4. Gately MK. Warrier RR. Honasoge S. et al. Administration of recombinant IL-12 to normal mice enhances cytolytic activity and induces production of IFN-γ in vivo. Int Immunol 1994:6:157-67.
5. Orange JS. Salazar-Mather TP. Opal SM. et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J Exp Med 1995:181:901-14.
6. Coughlin CM. Wysocka M. Kurzawa WM. Lee G. Trinchieri G. Eck SL. B7-I and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 1995:55:4980-7.
7. Marshall E. Cancer trial of interleukin-12 halted. Science 1995; 268:1555.
8. Tahara H, Zeh HJ, Storkus WJ. et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma invivo. Cancer Res 1994;54:182-9.
9. Zitvogel L. Tahara H. Robbins PD. et al. Cancer immunotherapy of established tumors with IL-12: effective delivery of genetically engineered fibroblasts. J Immunol 1995:155:1393-103.
10. Tahara H. Zitvogel L. Storkus WJ. et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic vector. J Immunol 1995;154:6466-74.
11. Mek JB. Yim JH. Tsung K, Norton JA. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res 1995;55:4765-70.
12. Rakhmilevich AL. Turner J. Ford MJ. et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Nall Acad Sci USA 1996:93:6291-6.
13. North RJ. Bursuker I. T cell-mediated suppression of the concomitant antitumor immune response as an example of transplantation tolerance. Transplantation Proceed 1984:16:463-9.
14. + effector T cells during progressive growth of the P815 mastocytoma. Immunol 1985;54:47-56.
15. Horvath-Arcidiacono JA. Mostowski HS. Bloom ET. IL-12 administered in vivo to young and aged mice. Discrepancy between the effects on tumor growth in vivo and cytotoxic T lymphocyte generation ex vivo: dependence on IFN-γ. Int Immunol 1996:8: 661-73.
16. Noguch Y, Richards EC. Chen Y-T, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 1995:92:2219-23.
17. Brunda MJ. Gately MK. Interleukin-12: potential role in cancer therapy. In: Important advances in oncology 1995. DeVita VT. Heilman S. Rosenberg SA, eds. Philadelphia: p 3-18.
18. Sykes M. Szot GL, Nguyen PL. Pearson DA. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995;6:2429-38.
19. Wysocka M, Kubin M, Vieira LQ, et al. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 1995:25:672-6.
20. Snapper CM. Yamaguchi H. Urban JF Jr. Finkelman FD. Induction of Ly-6A/E expression by murine lymphocytes after in vivo immunization is strictly dependent upon the action of IFN-α/β and/or interferon-γ. Intern Immunol 1991;3:845-52.
21. Germann T, Rude E. Interleukin-12. Int Arch Immunol 1995:108: 103-12.
22. Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today 1996:17:214-7.
23. Stern LL. Tarby CM. Tamborini B. Truitt GA. Preclinical development of IL-12 as an anticancer drug: comparison to IL-2. Proc Amer Assoc Cancer Res 1994:35:520.
24. Mu J. Zou JP. Yamamoto N. et al. Administration of recombinant interleukin 12 prevents out growth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 1995;55:4404-8.
25. Brun MJ. Luistro J, Hendrzak JA. Fountoulakis M, Garotta G. Gately MK. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother 1995:17:71-7.
26. Jenks S. After initial setback. IL-12 regaining popularity. J Natl Cancer Inst 1996;88:576-7.
27. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995; 270:908.
28. Colombo MP, Vagliani M, Spreafico F, et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996:56:2531-4.
29. Tan J. Newton CA. Djeu JY, et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in murine renal carcinoma model. Cancer Res 1996;56:3399-403.
30. Rakhmilevi AL. Janssen K, Turner J, Culp J. Yang N-S. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of IL-12. Human Gene Therapy 1997:8: 1303-11.